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Case Report
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Abstract
To the best of our knowledge this is the first case of this nature described in the literature. Sharing the authors experience
with this case, particularly the technical challenges and post-operative management may aid other physicians facing similar
scenarios. In this report, we describe a pancreaticoduodenectomy for pancreatic adenocarcinoma in a patient with a previ-
ous left ventricular assist device (LVAD). A multidisciplinary approach, particularly close involvement of the advanced heart
failure, mechanical heart and pancreas surgery teams was key to the success of this case. Major abdominal surgery in the
setting of previous LVAD should be considered carefully, however, the LVAD should not be generalized as an absolute
contraindication.
INTRODUCTION
Over 2500 continuous left ventricular assist devices (LVAD)
devices were implanted in United States in 2014 and over
20 000 have been implanted worldwide to date [1]. With the
increasing prevalence of ventricular assist devices, non-
cardiac surgeries for this patient population are becoming a
more frequently encountered clinical scenario. Patients with
adenocarcinoma of the head of the pancreas who undergo sur-
gery and adjuvant therapy have a 5-year survival of approxi-
mately 20% [2]. Patients with adenocarcinoma of the pancreas
who are not surgical candidates and receive only chemother-
apy with or without radiation have a median survival of ~7–10
months [3]. Clearly, surgery plays a critical role in the potential
survival of patients with adenocarcinoma of the pancreas.
Herein, we present a patient with an LVAD who was subse-
quently diagnosed with adenocarcinoma of the head of the
pancreas. After careful consideration of the overall prognosis
in this patient with this complex clinical presentation, we
elected to perform a pancreaticoduodenectomy.
CASE REPORT
A 66-year-old male with New York Heart Association (NYHA)
stage IV heart failure, severe aortic stenosis, severe aortic insuf-
ficiency and porcelain aorta underwent implantation of a
HeartMate II LVAD as destination therapy by the Cardiac
Transplant and Mechanical Heart Service at our institution on
October 26, 2013. Nine months later, routine laboratory follow
up done July 20, 2014 revealed an elevated total bilirubin of 6.3
(0.2–1.1mg/dL). Abdominal ultrasound showed cholelithiasis
and intra- and extra-hepatic biliary ductal dilation. Abdominal
computed tomography (CT) was not able to delineate the distal
common bile duct or pancreas head area due to LVAD artifact
(Figs. 1a and b). At this point, the patient’s anticoagulation was
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reversed and the patient underwent endoscopic retrograde cho-
langiopancreatography (ERCP). Fluoroscopy for the ERCP was
limited by the LVAD, however, a tight distal common bile duct
stricture of about 2 cm in length was noted (Fig. 2). ERCP was
followed immediately by endoscopic ultrasound (EUS) that
showed a 2.8 cm pancreatic head mass (Fig. 3). On EUS, the
mass was not abutting the portal vein, superior mesenteric
vein, superior mesenteric artery or celiac artery. Also, there
was no significant lymphadenopathy per EUS. Fine needle
aspiration of the pancreatic head mass was consistent with
adenocarcinoma. Rest of the work-up included a chest-CT
which was negative for metastatic disease, CA19-9 was 27
(0–37 U/mL). The case was discussed at our multidisciplinary
liver and pancreas tumor board and after several care confer-
ences with the family and involved providers, the decision
was made to proceed with a pancreaticoduodenectomy on
August 14, 2014.
Initial diagnostic laparoscopy was negative for metastatic
disease, and confirmed expected adhesions to the LVAD Gortex
pouch that is fashioned from the diaphragm (Fig. 4). After con-
firming the absence of metastatic disease, we then proceeded
with a standard pancreaticoduodenectomy. We also had to do
a small segment side bite resection of the portal vein with pri-
mary repair due to suspected involvement. He tolerated the
Figure 1: (a) Cross sectional imaging as a pre-operative study to define the pan-
creatic anatomy is limited by the LVAD artifact. (b) Computed tomography
scout film shows the location of the LVAD and LVAD driveline in the chest and
abdomen.
Figure 2: ERCP images illustrate the common bile duct with distal stricture, par-
tially obstructed by the LVAD.
Figure 3: Endoscopic ultrasound images of the adenocarcinoma of the head of
the pancreas.
Stomach
LVAD Gortex pouch
Figure 4: A pouch made of Gortex and secured to the inferior face of the dia-
phragm houses the LVAD and sits over the mid and upper quadrants of the
abdomen.
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procedure well and without any blood transfusions, estimated
blood loss was 200mL. He was extubated at the end of the case
and was transferred to the Cardiac Intensive Care Unit for fur-
ther care. A drain left around the hepatico and pancreatico
jejunal anastomosis was removed on post-operative Day #3
after checking the amylase level per our institutional protocol.
By post-operative Day #8 he was tolerating a regular soft diet
and having regular bowel function. He did not have any infec-
tious or bleeding complications post-operatively. He stayed in
the hospital until post-operative Day #17 mainly for close man-
agement of his overall fluid status and optimizing anticoagula-
tion per the Mechanical Heart team. His final pathology
showed a 3.0 cm, well differentiated tumor, without lympho-
vascular invasion, with peri-neural invasion, with three lymph
nodes positive by direct extension out of 17 total, surgical mar-
gins clear of cancer, Stage IIB, T3N1M0.
Approximately 6 weeks after surgery, he was started on
adjuvant chemotherapy with single agent Gemcitabine. He
completed total of 6 months of Gemcitabine without major side
effects.
At the time this report was drafted, the patient was 30 months
out from surgery with no evidence of recurrent disease.
DISCUSSION
Pancreatic cancer pre-operative imaging
Due to LVAD streaking artifact on CT, pre-operative good qual-
ity imaging of the pancreas was only possible with endoscopic
ultrasound.
Surgical challenges
Incision (presence of the LVAD driveline—Fig. 3)
Our incision had to be altered from our standard midline supra-
umbilical incision in order to avoid the driveline (Fig. 5). As
depicted in Figs 1a and b, the LVAD pump occupies a significant
amount of the left abdominal wall from the costal margin to the
umbilicus. The driveline also loops across the abdomen and
exits in the left abdominal wall. The surgeon needs to be aware
of these factors and be flexible with the location of the incision.
Retraction and exposure
Components of the inflow and outflow cannulas of the LVAD
are made of pliable materials, therefore continuous intra-
operative flow monitoring by a mechanical heart engineer is
required for these cases.
Linear flow (HeartMate CF) and identification of vascular
structures
Identification of the superior mesenteric artery, celiac artery,
hepatic artery, gastroduodenal artery or any arterial anatomic
variants (i.e. replace right hepatic artery) is key to the oper-
ation. In patients with previous LVAD the lack of arterial pulsa-
tile flow makes identification of these structures by palpation
or Doppler not possible. Intra-operative ultrasound plays a big-
ger role for identification of vascular structures.
Post-operative anticoagulation
LVAD patients are routinely kept anticoagulated with a target
INR (international normalized ratio) between 1.8 and 2.5. In our
case, the INR was corrected and the patient was kept on a hep-
arin drip until two hours prior to surgery. Full dose intra-
venous heparin drip was started on post-operative Day 2 and
Coumadin was started on post-operative Day 3.
CONCLUSION
Close collaboration with the LVAD team is key to the successful
care of these patients. Based on our limited experience, cur-
rently at our institution previous history of LVAD is not an abso-
lute contraindication for major abdominal oncologic surgery.
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Figure 5: Dotted line shows the subcutaneous location of the driveline (LVAD
power cord). A typical midline incision or subcostal incision was not feasible
due to the driveline trajectory.
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